August 14, 2024
Eli Lilly Unveils State-of-the-Art Genetic Medicine Research Center in Boston
Eli Lilly, Boston, genetic medicines, research center, innovation hub, biotech
Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks
Metagenomi, ALS program, Biogen, Ionis, pharmaceutical industry, drug development, layoffs, market challenges
AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment
AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient
Rivus Advances in Obesity-Related Heart Failure with Mid-Stage Success of HU6
Rivus Pharmaceuticals, HU6, obesity-related heart failure, Phase IIa HuMAIN trial, controlled metabolic accelerator, muscle-preserving weight loss
Novo Nordisk Pursues FDA Filing for Once-Weekly Insulin and Semaglutide Combo After Icodec Rejection
Novo Nordisk, insulin icodec, semaglutide, FDA filing, type 2 diabetes, once-weekly insulin, IcoSema, COMBINE-1 study, regulatory approval
Lilly Opens State-of-the-Art Research and Development Center in Boston
Lilly, Boston, research and development, genetics research, biotech incubator, East Coast hub
Lexicon Pharmaceuticals Reduces Workforce by 50% to Focus on Diabetes Drug
Lexicon Pharmaceuticals, workforce reduction, diabetes drug, restructuring, Zynquista
Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis
Galderma’s IL-31 Blocker Nemluvio Gains FDA Approval for Prurigo Nodularis
Galderma, Nemluvio, IL-31 blocker, FDA approval, prurigo nodularis, therapeutic dermatology